Insilico Medicine and Eli Lilly inked a commercialization arrangement tied to Insilico’s AI-discovered preclinical candidates for oral therapeutics. The deal includes an upfront payment of $115 million and potential milestone payments of about $2.75 billion in “biobucks,” with Lilly’s rights covering development, manufacturing and commercialization for selected assets.